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Introduction and Objective: The cost and utilisation of the insulin analogue (Insulin glargine) has 
grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on 
average by 291% per year. This growth has been driven by an increasing number of successful law 
suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) 
insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic 
review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with 
Type I diabetes. As a result, provide published data to support future recommended activities by the 
State to limit its use. Methods: A systematic review of published studies between January 1970 and 
July 2009 using established methods documenting the effectiveness of insulin glargine in patients 
with Type 1 diabetes. Only randomised controlled clinical trials included
1
. Results: Out of 803 studies, 
only 8 met the inclusion criteria. Most were of poor methodological quality or had a high risk of bias. 
No study could be classified as double-blind, and only one study documented increased efficacy of 
insulin glargine in relation to both glycaemic control and hypoglycaemic episodes. Typically, there was 
no significant difference between insulin glargine and NPH insulins in terms of their effectiveness
1
. 
Conclusions: This systematic review showed no therapeutic benefit with insulin glargine over other 
insulin formulations although considerable cost differences. This was similar to the findings from other 
world-renowned organizations and other published studies, which showed at best only minor health 
gain from long-acting insulins vs. standard (NPH) insulins
1,2
. We therefore recommend to the State 
Authorities to delist insulin glargine or renegotiate a price reduction for continued listing. This is in line 
with activities undertaken by authorities in other countries
1
. This systematic review provides support 
for this decision as well as documentation to combat potential law suits if there cannot be satisfactory 
discussions. Consequently, we recommend this approach to other health authorities. 
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